Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
Not yet recruiting · NCT06456138 · Registry updated 2024-06-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC | neoplasm | Not yet recruiting | Phase 1 / Phase 2 | 2024-06-13 | NCT06456138 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| BeiGene | 47 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 88 |
| Novartis | 114 |
| Shanghai Chest Hospital | 116 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Shanghai Chest Hospital | Shanghai | China | 56 |